| Product Code: ETC7659010 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Dhaval Chaurasia | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Israel Pharmacogenetics Testing in Psychiatry/Depression Market Overview |
3.1 Israel Country Macro Economic Indicators |
3.2 Israel Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume, 2021 & 2031F |
3.3 Israel Pharmacogenetics Testing in Psychiatry/Depression Market - Industry Life Cycle |
3.4 Israel Pharmacogenetics Testing in Psychiatry/Depression Market - Porter's Five Forces |
3.5 Israel Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume Share, By Type, 2021 & 2031F |
3.6 Israel Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume Share, By Test Type, 2021 & 2031F |
3.7 Israel Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume Share, By Gene Type, 2021 & 2031F |
3.8 Israel Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume Share, By Patient Type, 2021 & 2031F |
3.9 Israel Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume Share, By Product, 2021 & 2031F |
3.10 Israel Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume Share, By End User, 2021 & 2031F |
3.11 Israel Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume Share, By Distribution Channel, 2021 & 2031F |
4 Israel Pharmacogenetics Testing in Psychiatry/Depression Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing awareness and acceptance of personalized medicine in psychiatry |
4.2.2 Rising prevalence of mental health disorders in Israel |
4.2.3 Growing adoption of pharmacogenetic testing by healthcare providers |
4.3 Market Restraints |
4.3.1 Limited reimbursement policies for pharmacogenetics testing in Israel |
4.3.2 Regulatory challenges and uncertainties surrounding genetic testing in psychiatry |
4.3.3 High costs associated with pharmacogenetic testing |
5 Israel Pharmacogenetics Testing in Psychiatry/Depression Market Trends |
6 Israel Pharmacogenetics Testing in Psychiatry/Depression Market, By Types |
6.1 Israel Pharmacogenetics Testing in Psychiatry/Depression Market, By Type |
6.1.1 Overview and Analysis |
6.1.2 Israel Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume, By Type, 2021- 2031F |
6.1.3 Israel Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume, By Anxiety, 2021- 2031F |
6.1.4 Israel Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume, By Mood Disorders, 2021- 2031F |
6.1.5 Israel Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume, By Depression, 2021- 2031F |
6.1.6 Israel Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume, By Bipolar Disorders, 2021- 2031F |
6.1.7 Israel Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume, By Psychotic Disorders, 2021- 2031F |
6.1.8 Israel Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume, By Eating Disorders, 2021- 2031F |
6.2 Israel Pharmacogenetics Testing in Psychiatry/Depression Market, By Test Type |
6.2.1 Overview and Analysis |
6.2.2 Israel Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume, By Whole Genome Sequencing, 2021- 2031F |
6.2.3 Israel Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume, By Chromosomal Array-Based Tests, 2021- 2031F |
6.3 Israel Pharmacogenetics Testing in Psychiatry/Depression Market, By Gene Type |
6.3.1 Overview and Analysis |
6.3.2 Israel Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume, By CYP2C19, 2021- 2031F |
6.3.3 Israel Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume, By CYP2C9 AND VKORC1, 2021- 2031F |
6.3.4 Israel Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume, By CYP2D6, 2021- 2031F |
6.3.5 Israel Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume, By HLA-B, 2021- 2031F |
6.3.6 Israel Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume, By HTR2A/C, 2021- 2031F |
6.3.7 Israel Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume, By HLA-A, 2021- 2031F |
6.4 Israel Pharmacogenetics Testing in Psychiatry/Depression Market, By Patient Type |
6.4.1 Overview and Analysis |
6.4.2 Israel Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume, By Child, 2021- 2031F |
6.4.3 Israel Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume, By Adult, 2021- 2031F |
6.4.4 Israel Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume, By Geriatric, 2021- 2031F |
6.5 Israel Pharmacogenetics Testing in Psychiatry/Depression Market, By Product |
6.5.1 Overview and Analysis |
6.5.2 Israel Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume, By Instruments, 2021- 2031F |
6.5.3 Israel Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume, By Consumables, 2021- 2031F |
6.5.4 Israel Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume, By Software & Services, 2021- 2031F |
6.6 Israel Pharmacogenetics Testing in Psychiatry/Depression Market, By End User |
6.6.1 Overview and Analysis |
6.6.2 Israel Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume, By Hospitals & Clinics, 2021- 2031F |
6.6.3 Israel Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume, By Dignostics Laboratories, 2021- 2031F |
6.6.4 Israel Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume, By Academic And Research Institutes, 2021- 2031F |
6.6.5 Israel Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume, By Others, 2021- 2031F |
6.7 Israel Pharmacogenetics Testing in Psychiatry/Depression Market, By Distribution Channel |
6.7.1 Overview and Analysis |
6.7.2 Israel Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume, By Direct Tender, 2021- 2031F |
6.7.3 Israel Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume, By Third-Party Distribution, 2021- 2031F |
6.7.4 Israel Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume, By Others, 2021- 2031F |
6.7.5 Israel Pharmacogenetics Testing in Psychiatry/Depression Market Revenues & Volume, By Others, 2021- 2031F |
7 Israel Pharmacogenetics Testing in Psychiatry/Depression Market Import-Export Trade Statistics |
7.1 Israel Pharmacogenetics Testing in Psychiatry/Depression Market Export to Major Countries |
7.2 Israel Pharmacogenetics Testing in Psychiatry/Depression Market Imports from Major Countries |
8 Israel Pharmacogenetics Testing in Psychiatry/Depression Market Key Performance Indicators |
8.1 Adoption rate of pharmacogenetic testing in psychiatric practices |
8.2 Number of research studies validating the effectiveness of pharmacogenetics in psychiatry |
8.3 Level of collaboration between pharmaceutical companies and genetic testing laboratories for developing tailored treatments |
9 Israel Pharmacogenetics Testing in Psychiatry/Depression Market - Opportunity Assessment |
9.1 Israel Pharmacogenetics Testing in Psychiatry/Depression Market Opportunity Assessment, By Type, 2021 & 2031F |
9.2 Israel Pharmacogenetics Testing in Psychiatry/Depression Market Opportunity Assessment, By Test Type, 2021 & 2031F |
9.3 Israel Pharmacogenetics Testing in Psychiatry/Depression Market Opportunity Assessment, By Gene Type, 2021 & 2031F |
9.4 Israel Pharmacogenetics Testing in Psychiatry/Depression Market Opportunity Assessment, By Patient Type, 2021 & 2031F |
9.5 Israel Pharmacogenetics Testing in Psychiatry/Depression Market Opportunity Assessment, By Product, 2021 & 2031F |
9.6 Israel Pharmacogenetics Testing in Psychiatry/Depression Market Opportunity Assessment, By End User, 2021 & 2031F |
9.7 Israel Pharmacogenetics Testing in Psychiatry/Depression Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F |
10 Israel Pharmacogenetics Testing in Psychiatry/Depression Market - Competitive Landscape |
10.1 Israel Pharmacogenetics Testing in Psychiatry/Depression Market Revenue Share, By Companies, 2024 |
10.2 Israel Pharmacogenetics Testing in Psychiatry/Depression Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here